SDC, Figure S1

**SDC - Figure S1.** ROC curve analysis of TCL1A and CD79B gene expression in B cells. Gene expression levels at time of acute rejection were analysed by logistic regression yielding an area under the curve (AUC) of 0.86 for TCL1A (95% CI 0.73 – 0.99) and 0.76 for CD79B (95% CI 0.59 – 0.93). When an unbiased cut-off point for TCL1A (median of all samples at time of AR and control: TCL1A/reference genes = 186 x10^{-3}) is used, the sensitivity for AR detection is 81.3% and the specificity is 80%. When the median CD79B value at time of AR and controls (CD79B/reference genes = 99 x10^{-3}) is used, the sensitivity for AR detection is 62.5% and the specificity is 62.5%. Combination of the two genes did not increase sensitivity or specificity.

SDC, Figure S2
**SDC - Figure S2.** TCL1A and CD79B gene expression levels in PBMC increase after successful anti-rejection treatment. Two patients were monitored at pre-transplant, discharge, at time of acute rejection (before initiation of anti-rejection treatment) and after successful anti-rejection treatment (indicated as follow-up, 11 and 18 days after treatment initiation, respectively). Ratios of (A) TCL1A and (B) CD79B gene expression to reference genes are shown.